[[Publications List]](publications.md)  [[CABS Ranked]](ref.md)  [[By Year]](by_year.md)  [[Policy Impact]](policy_citations.md)

# Clinical Trials

_The following is a list of Clinical trials by therapeutic areas which I have coordinated as Senior Statistician at the Hellenic Cooperative Oncology Group (HeCOG). Clinicaltrials.gov identifier in brackets_

---

## Lung Cancer

**[5]** ClinicalTrials.gov Identifier: **[NCT03568097](https://clinicaltrials.gov/study/NCT03568097)** - PAVE: Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung Cancer [Phase II]

   * Mountzios, G., Papadopoulou, K., <ins>Korfiatis, N.</ins>, Goussia, A., Samantas, E., Aravantinos, G., Christopoulou, A., Spathas, N., Fountzilas, E., Psyrri, A., Koliou, G., Meditskou, S., Kosmas, E., Bobos, M., Charchanti, A., Vamvakaris, I., Koumarianou, A., Bafaloukos, D., Kosmidis, P., Fountzilas, G., & Linardou, H. (2025). Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final Outcome, Immunophenotypic and biomarker analysis. *European Journal of Cancer*, Vol. 228, pp. 115660.

   * Mountzios, G., Papadopoulou, K., <ins>Korfiatis, N.</ins>, Goussia, A., Samantas, E., Aravantinos, G., Christopoulou, A., Spathas, N., Fountzilas, E., Psyrri, A., Koliou, G., Meditskou, S., Kosmas, E., Bobos, M., Charchanti, A., Vamvakaris, I., Koumarianou, A., Bafaloukos, D., Kosmidis, P., Fountzilas, G., & Linardou, H. (2024). Final outcome, immunophenotypic and biomarker analysis of intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (PAVE). *ESMO Open*, Vol. 9, pp. 102770. [DOI](https://doi.org/10.1016/j.esmoop.2024.102770)

**[4]** ClinicalTrials.gov Identifier: **[NCT05372081](https://clinicaltrials.gov/study/NCT05372081)** - SNF-CLIMEDIN: Digital support and intervention in patients with advanced NSCLC [Non-interventional]

   * Kosmidis, P., Kosmidis, T., Papadopoulou, K., <ins>Korfiatis, N.</ins>, Vozikis, A., Lampaki, S., Psyrri, A., Fountzilas, E., Christopoulou, A., Samantas, E., Vagionas, A., Mountzios, G., Gkoumas, G., Tsoukalas, N., Athanasiadis, I., Bafaloukos, D., Panopoulos, C., Koufaki, M., Fountzilas, G., & Linardou, H. (2025). SNF-CLIMEDIN: A HECOG prospective randomized trial of digital support and intervention in patients with advanced NSCLC—Final results. *Journal of Clinical Oncology*, Vol. 43, No. 16_suppl, pp. 1515-1515.

   * Kosmidis, P., Kosmidis, T., Papadopoulou, K., <ins>Korfiatis, N.</ins>, Vozikis, A., Lampaki, S., Psyrri, A., Fountzilas, E., Christopoulou, A., Samantas, E., Vagionas, A., Mountzios, G., Gkoumas, G., Tsoukalas, N., Athanasiadis, I., Bafaloukos, D., Panopoulos, C., Koufaki, M., Fountzilas, G., & Linardou, H. (2025). Frequency of Adverse Events Reported Digitally by Patients with Advanced NSCLC: Analysis From CLIMEDIN, a HeCOG Study. *Journal of Thoracic Oncology*, Vol. 20, No. 10, pp. S392.

   * Linardou, H., Kosmidis, T., Papadopoulou, K., <ins>Korfiatis, N.</ins>, Vozikis, A., Lampaki, S., Psyrri, A., Fountzilas, E., Christopoulou, A., Samantas, E., Vagionas, A., Mountzios, G., Gkoumas, G., Tsoukalas, N., Athanasiadis, I., Bafaloukos, D., Panopoulos, C., Koufaki, M., Fountzilas, G., & Kosmidis, P. (2024). Analysis of evolution of patient reported side effects during treatment for advanced NSCLC. *Annals of Oncology*, Vol. 35, pp. S863-S864.

   * Kosmidis, P., Kosmidis, T., Papadopoulou, K., <ins>Korfiatis, N.</ins>, Vozikis, A., Lampaki, S., Psyrri, A., Fountzilas, E., Christopoulou, A., Samantas, E., Vagionas, A., Mountzios, G., Gkoumas, G., Tsoukalas, N., Athanasiadis, I., Bafaloukos, D., Panopoulos, C., Koufaki, M., Fountzilas, G., & Linardou, H. (2024). SNF-CLIMEDIN: A prospective randomized trial of digital intervention in patients with advanced NSCLC—A HeCOG study. *Journal of Clinical Oncology*, Vol. 42, No. 16_suppl, pp. 1520-1520.

   * Linardou, H., Kosmidis, T., Papadopoulou, K., <ins>Korfiatis, N.</ins>, Lampaki, S., Psyrri, A., Fountzilas, E., Christopoulou, A., Samantas, E., Vagionas, A., Mountzios, G., Gkoumas, G., Tsoukalas, N., Athanasiadis, I., Bafaloukos, D., Panopoulos, C., Koufaki, M., Vozikis, A., Fountzilas, G., & Kosmidis, P. (2023). Clinical and molecular study with digital support of advanced non-small cell lung cancer patients: SNF-CLIMEDIN, a prospective randomized Hellenic Cooperative Oncology Group study. *Annals of Oncology*, Vol. 34, pp. S816-S817.

---

## Colorectal Cancer

**[3]** ClinicalTrials.gov Identifier: **[NCT03311750](https://clinicaltrials.gov/study/NCT03311750)** - A-REPEAT: Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer [Phase II]

   * Sgouros, J., Eliades, A., Papadopoulou, K., <ins>Korfiatis, N.</ins>, Papamichael, D., Fountzilas, E., Tsolaki, E., Achilleos, A., Tsangaras, K., Loizides, C., Oikonomopoulos, G., Makatsoris, T., Kypri, E., Ioannides, M., Koumbaris, G., Fountzilas, G., Patsalis, P., & Pentheroudakis, G. (2025). Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping. *ESMO Gastrointestinal Oncology*, Vol. 7, pp. 100120. [DOI](https://doi.org/10.1016/j.esmogo.2024.100120)

---

## Prostate Cancer

**[2]** ClinicalTrials.gov Identifier: **[NCT02512458](https://clinicaltrials.gov/study/NCT02512458)** - CabaBone: Cabazitaxel in patients with castration-resistant prostate cancer and osseous metastases [Translational]

   * Liontos, M., Goussia, A., <ins>Korfiatis, N.</ins>, Papadopoulou, K., Kanellis, G., Visvikis, A., Petrakis, G., Tsiatas, M., Fountzilas, E., Samantas, E., Fountzilas, G., & Efstathiou, E. (2025). The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer: A Hellenic Cooperative Oncology Group Phase II Study. *Clinical Genitourinary Cancer*, Vol. 23, No. 1, pp. 102253. [DOI](https://doi.org/10.1016/j.clgc.2024.102253)

---

## Breast Cancer

**[1]** ClinicalTrials.gov Identifier: **[NCT04829890](https://clinicaltrials.gov/study/NCT04829890)** - Dose-dense sequential adjuvant chemotherapy in patients with resected high-risk breast cancer [Phase III]

   * Goussia, A., Dimitrakopoulos, F., <ins>Korfiatis, N.</ins>, Koletsa, T., Batistatou, A., Kourea, H., Bobos, M., Papadopoulou, K., Charchanti, A., Bai, M., Tzaida, O., Petraki, K., Arapantoni-Dadioti, P., Psyrri, A., Gogas, H., Zagouri, F., & Fountzilas, G. (2025). Clinical outcomes and important prognostic biomarkers following dose-dense sequential adjuvant chemotherapy (dds-CT) in early breast cancer (eBC): Pooled-analysis of individual patient data. *ESMO Open*, Vol. 10, pp. 104621. [DOI](https://doi.org/10.1016/j.esmoop.2025.104621)
